Summary Tirapazamine (SR 4233), a bioreductive drug selectively toxic towards hypoxic cells, is presently in phase II clinical trials. Since it would not be expected that all tumours would respond equally to the drug, we are exploring ways of predicting the response of individual tumours. In this study we have tested whether the comet assay, which measures DNA damage in individual cells, can provide a simple, surrogate end point for cell killing by tirapazamine. We examined the relationship between the cytotoxicity of tirapazamine under hypoxic conditions and tirapazamine-induced DNA strand breaks in murine (SCCVII, EMT6, RIF-1) and human (HT1080, A549, HT29) tumour cell lines. These results were compared with the relationship between tirapazamine cytotoxicity and another measure of the ability of cells to metabolise tirapazamine; highperformance liquid chromatography (HPLC) analysis of tirapazamine loss or formation of the two electron reduction product SR 4317. The correlation between the hypoxic cytotoxic potency of tirapazamine and DNA damage was highly significant (r=0.905, P=0.013). A similar correlation was observed for hypoxic potency and tirapazamine loss (r=0.812, P=0.050), while the correlation between hypoxic potency and SR 4317 formation was not significant (r=0.634, P=0.171). The hypoxic cytotoxicity of tirapazamine in vitro can therefore be predicted by measuring tirapazamine-induced DNA damage using the comet assay. This approach holds promise for predicting the response of individual tumours to tirapazamine in the clinic.
Many human tumours contain a significant subpopulation of cells at low oxygen tensions (H6ckel et al., 1991; MuellerKleiser et al., 1991; Vaupel et al., 1991) . These hypoxic cells, which can present a problem in the radiotherapy of solid tumours (Bush et al., 1978; Gatenby et al., 1988; Hockel et al., 1993) , are probably also resistant to many chemotherapeutic agents (Tannock, 1978; Hughes et al., 1989; Wilson and Denny, 1992) . It has recently been proposed that with the use of bioreductive drugs, which are selectively activated to a cytotoxic species under hypoxic conditions, it may be possible to exploit hypoxic tumour cells so that their presence in solid tumours is an advantage rather than a disadvantage (Brown and Koong, 1991; Denny and Wilson, 1993; Brown and Giaccia, 1994) . This promising approach is about to be tested in the clinic with two new bioreductive drugs in, or about to enter, clinical trials; the benzotriazine di-N-oxide tirapazamine (SR 4233, WIN 59075) (Brown, 1993; Doherty et al., 1994) and the dual-function alkylating nitroimidazole RB 6145 (or the less emetic R isomer PD 144872) (Cole et al., 1992; Sebolt-Leopold et al., 1993) .
In the clinic it is expected that only patients with tumours containing a significant proportion of hypoxic cells would respond to a bioreductive drug that is selectively toxic towards hypoxic cells. The response of a tumour to any such bioreductive drug will depend both on the level of activity of the reductase(s) that activate the drug to a cytotoxic species, and the level of tumour hypoxia. Recent studies have shown that reductase activity can vary substantially between different human tumour cell lines (Plumb et al., 1994; Robertson et al., 1994) , and measurements made using oxygen electrodes show large variations in oxygen tensions between tumours . It would therefore be highly desirable to be able to predict the response of individual tumours to a bioreductive drug so that patients unlikely to benefit from the drug would not be treated with it, and further, the power of a clinical trial of the drug to produce a significant response would be improved.
Tirapazamine exhibits high hypoxia-selective cytotoxicity in the order of 50 to 200-fold in most rodent and human cell lines (Zeman et al., 1986 (Zeman et al., , 1988 Stratford and Stephens, 1989) . Tirapazamine also kills hypoxic cells in transplanted tumours in mice (Zeman et al., 1988; Kim and Brown, 1994; Durand, 1994) and has been shown to potentiate the effects of modalities that are more toxic towards aerobic tumour cells. In particular, a large potentiation of tumour cell kill has been observed with fractionated radiation (Brown and Lemmon, 1990, 1991) and with some chemotherapeutic agents, particularly cisplatin (Dorie and Brown, 1993) . Tirapazamine is currently in phase II clinical trials in combination with radiation and with cisplatin.
The metabolic activation of tirapazamine involves one electron reduction to a free radical species which, in the presence of oxygen, is back-oxidised to regenerate the parent drug with concomitant production of superoxide. Under hypoxic conditions the tirapazamine radical can abstract a hydrogen atom from DNA and produce a DNA strand break (Figure 1 ). The hypoxic cytotoxicity of tirapazamine is due to the formation of DNA double-strand breaks (dsbs) and resulting chromosome aberrations (Biedermann et al., 1991; Wang et al., 1992) . Although it would be desirable to measure the cytotoxic lesion directly, it is probable that the low yield of dsbs in hypoxic cells treated with tirapazamine (Zeman and Brown, 1989; Olive, 1995a) would preclude measurement of dsbs using clinically achievable drug doses. We propose that the alkaline comet assay, which measures DNA single-strand breaks (ssbs) in individual cells (Olive et al., 1990) , may be used as a predictive assay for tumour response to tirapazamine. For this to hold, the ratio of DNA ssbs to dsbs would have to be constant across cell lines and the number of initial dsbs (and hence ssbs) predictive of cell kill. DNA damage measured using the comet assay should be a function of both the level of tumour hypoxia and reductase activity. In the present study we have assessed the relationship between tirapazamine-induced DNA damage and cytotoxicity in a number of murine (SCCVII, EMT6, RIF-1) and human (HT1080, A549, HT29) tumour cell lines treated with tirapazamine under hypoxic conditions. We have compared this with the correlation between hypoxic cytotoxicity and another measure of cells' ability to metabolise tirapazamine; high-performance liquid chromatography (HPLC) analysis of tirapazamine loss and formation of the two electron reduction product SR 4317 (Figure 1 Hypoxic drug exposures Hypoxic drug exposures were performed in double sidearmed glass flasks (Wheaton Jacketed Reaction Vessels) at 37°C with continuous stirring using glass-coated magnetic stir bars. Tirapazamine solutions (9 ml), in alpha minimal essential medium (MEM) containing 10% FBS and antibiotics as above, at 1.25 times the final required drug concentration were equilibrated with humidified gas (nitrogen-5% carbon dioxide) for 60 min before sampling of 1 ml for HPLC analysis. Drug exposure was initiated by addition of cells (2 ml at 2.5 x 106 cells ml-' equilibrated under the same conditions). Samples of 0.5 ml (2.5 x 105 cells) were taken after 5 min drug exposure and added to ice-cold phosphate-buffered saline (PBS) to give a final density of 2 x 104 cells ml-' for determination of DNA damage using the comet assay. After 60 min drug exposure, samples were taken to determine cytotoxicity and for HPLC analysis of tirapazamine and SR 4317 concentrations. Colony formation was assessed after incubation at 37°C for 8 (EMT6), 9 (SCCVII), 10 (HT1080), 12 (RIF-1, A549) or 14 days (HT29) by staining with 0.25% crystal violet in 95% ethanol and counting colonies containing >50 cells.
Comet assay
The alkaline comet assay was performed as described previously by Olive and coworkers . Briefly, 0.5 ml of cell suspension (2 x 104 cells ml-' in cold PBS) was added to 1.5 ml of a 1% solution of low gelling temperature agarose (Sigma Type VII), mixed and pipetted onto a microscope slide on a cold block. The slides were placed in alkaline lysis solution (30 mm sodium hydroxide, 1 M sodium chloride, 0.1% Nlauroylsarcosine) for 60 min, then washed for 3 x 20 min in alkaline rinse solution (30 mM sodium hydroxide, 2 mM EDTA), followed by electrophoresis at 0.4 V cm-' for 25 min in a fresh solution of 30 mm sodium hydroxide, 2 mM EDTA. Slides were rinsed with distilled water for 15 min, then stained with propidium iodide (2.5 Mg ml-') for 15 min.
The neutral comet assay was performed as described by Olive (1995a) . Slides prepared as above were placed in lysis solution (0.5% sodium dodecyl sulphate, 30 mM EDTA, pH 8.3) at 50°C for 4 h. Some slides were incubated overnight at 37°C with 0.5 mg ml-' proteinase K. After lysis slides were washed for at least 6 h in rinse buffer (90 mM tris, 90 mM boric acid, 2 mM EDTA, pH 8.5), followed by electrophoresis at 0.6 V cm-' for 25 min in fresh rinse buffer.
All slides were analysed within 48 h. 
Results
The cytotoxicity of tirapazamine towards three human (HT1080, A549, HT29) and three murine (SCCVII, RIF-1, EMT6) tumour cell lines was assessed under hypoxic conditions and correlated with three measures of drug metabolism determined in the same experiments: production of tirapazamine-induced DNA strand breaks, loss of tirapazamine and formation of SR 4317. HPLC analysis of metabolism Tirapazamine solutions were equilibrated with nitrogen-5% carbon dioxide for 60 min before initiation of drug exposure by addition of cells equilibrated under identical conditions. Before mixing, samples were taken for HPLC analysis to check for evaporative loss of water from the drug solutions. There was consistent, reproducible metabolism of tirapazamine in media gassed under hypoxic conditions, as indicated by detection of the two-electron reduction product SR 4317.
For an initial drug concentration of 50 gIM, approximately 0.5 gM SR 4317 was detected following 60 min gassing under hypoxic conditions, with a 2-fold higher concentration detected after 120 min (Table I ). This metabolism in the absence of cells was via the oxygen-sensitive one-electron reduction product as there was complete inhibition of metabolism when tirapazamine was gassed under aerobic conditions. Metabolism was also inhibited in PBS, although addition of FBS, cysteine or ascorbate to PBS at the concentrations present in a-MEM each resulted in some metabolism of tirapazamine, which increased with time of hypoxic gassing (Table I) . It thus appears that there are a number of reducing agents present in a-MEM that can chemically reduce tirapazamine under hypoxic conditions. Rates of cellular metabolism of tirapazamine were therefore corrected for this chemical reduction. Reduced glutathione, a reducing agent present in high concentrations in most cells, can also reduce tirapazamine under hypoxic conditions (Table I) .
The rate of metabolism of tirapazamine in hypoxic cultures, as measured by HPLC analysis of tirapazamine loss, or formation of SR 4317 in the extracellular media, increased linearly with tirapazamine concentration in each of the cell lines investigated (Figure 2a,b) (Figure  6g) , with the exception of the highest concentrations in the human cell lines where damage appeared to saturate, although cytotoxicity still increased (Figure 7 ). The murine cell lines all had similar sensitivities to induction of ssbs by tirapazamine, as did the human cell lines. For a given tirapazamine concentration there was about 2-fold greater DNA damage in the murine than in the human lines (Figure 6g ).
Cytotoxicity
The cytotoxicity of tirapazamine towards hypoxic cell cultures following a 60 min drug exposure was assessed by clonogenic survival curves over a range of drug concentrations ( Figure 7) . The murine tumour cell lines all had similar sensitivities to cell killing by tirapazamine under hypoxic conditions, and were 2-to 3-fold more sensitive than the human cell lines.
Relationship between sensitivity to tirapazamine and DNA damage As DNA damage was linearly related to tirapazamine concentration (Figure 6g) , the sensitivity to ssb production I -o a)
.0
.C was measured from the slope of the dose -response curves. These values were plotted against hypoxic cytotoxic potency, calculated as the reciprocal of the C1O value (drug concentration required to reduce survival to 10%) obtained by interpolation from Figure 7 . There was a highly significant correlation (r=0.905, P=0.013) between sensitivity to ssb production and hypoxic potency (Figure 8a ). The potency of tirapazamine towards the human cell lines was 2-to 3-fold lower than towards the murine lines, with tirapazamine producing 2-to 3-fold less DNA damage in the human than in the murine lines. Relationship between sensitivity to tirapazamine and metabolism First-order rate constants for loss of tirapazamine oi formation of SR 4317 were calculated from the slopes ol the plots in Figure 2 and plotted against hypoxic cytotoxic potency (Figures 8b and c) . There was a significani correlation (r=0.812, P=0.050) between the rate constant4 for tirapazamine loss and hypoxic potency, with tirapazamint being most potent against the SCCVII, RIF-1 and EMT6 cel lines and being metabolised fastest in those lines (Figure 8b Ostling and Johanson (1984) to video image analysis and reported many applications for the comet assay, including the detection of radiation-induced apoptosis (Olive et al., 1993b) , DNA dsbs (Olive et al., 1991) , and hypoxia in murine tumours Olive, 1995a,b) and in human breast tumours (Olive et al., 1993a) . The mechanism of hypoxic cytotoxicity of tirapazamine, by the formation of DNA dsbs and resulting chromosome breaks, suggested to us that the comet assay, which measures DNA strand breaks in individual cells, may predict for cell killing by tirapazamine under hypoxic conditions. While it would be preferable to measure the cytotoxic lesion (DNA dsbs) directly, the low yield of such lesions necessitates the use of supertoxic drug doses (Figure 3 ), which would clearly preclude the use of such an assay in clinical situations. The present study demonstrates a good correlation between tirapazamineinduced DNA ssbs and hypoxic cell killing by tirapazamine in vitro, suggesting fulfillment of the requirement that the ratio of DNA ssbs to dsbs would have to be constant across cell lines, and the number of initial dsbs and ssbs predictive of cell kill. The observed 2 to 3-fold greater sensitivity of the murine tumour cell lines to killing by tirapazamine under hypoxic conditions compared with the human lines is consistent with previously published data (Zeman et al., 1986; Biedermann et al., 1991) and appears to underlie the lower hypoxic cytotoxicity ratios (ratio of drug concentrations required to give the same level of killing under aerobic and hypoxic conditions) reported for tirapazamine in human than in murine cell lines (Zeman et al., 1986) . It should be recognised that, although the hypoxic selective cytotoxicity of tirapazamine is generally lower in human than murine cell lines, it is still substantial, with hypoxic cytotoxicity ratios of around 50 being common (Zeman et al., 1986) . Tirapazamine induced 2-to 3-fold more DNA damage in the hypoxic murine cell lines than in the human cell lines, indicating that the variation in hypoxic sensitivity could be entirely accounted for by the production of DNA strand breaks.
From the limited number of cell lines in the present study it appears that the correlation between DNA damage and cell survival could largely result from interspecies differences. The similar DNA damage and sensitivity of each of the human and each of the murine cell lines suggests that they must possess similar levels of activity of the reductase(s) that activates tirapazamine to a cytotoxic species. However, in the clinic, wide variations in reductase activity, as has been reported for human tumour cell lines (Plumb et al., 1994; Robertson et al., 1994) , and varying levels of hypoxia , would be expected to result in large differences in sensitivity to tirapazamine. It is of primary importance that in this study, by measuring DNA damage, it was possible to distinguish between cell lines with 2-to 3-fold differences in sensitivity to killing by tirapazamine under hypoxic conditions. Although we measured initial DNA damage after 5 min drug exposure, when the effects of repair should be minimal, and showed this to correlate with cytotoxicity after 60 min, it appears that, at least for the SCCVII cell line, DNA damage after 60 min also correlates with cytotoxicity (Figure 5b ). This augurs well for when this approach is tested in vivo in animal models, or in the clinic, as in these situations it will not be possible to measure initial DNA damage.
In the present study high numbers of ssbs were produced very rapidly in hypoxic cells treated with tirapazamine. median tail moment of approximately 13 was observed after 5 min exposure of hypoxic SCCVII cells to 15 gM tirapazamine (Figures 5a, 6g ), a drug concentration that produces about two logs of cell kill after 60 min drug exposure (Figure 7) . In SCCVII cells irradiated on ice with an equitoxic dose of y-rays [10 Gy, surviving fraction (SF) = 3.55 x 10-2, 2.55 x 10-2 and 2.40 x 10-2 in three independent experiments], a median tail moment of about 15 was observed (Figure 4) . , 1995) . Cell lines deficient in repair of DNA dsbs have been reported to be more sensitive to killing by tirapazamine under hypoxia than predicted from their rates of drug metabolism, suggesting that the ability to repair tirapazamine-induced dsbs is an important determinant of sensitivity to the drug (Biedermann et al., 1991) . The excellent correlation in the present study between tirapazamineinduced DNA damage and hypoxic cytotoxicity for all of the cell lines investigated suggests that there are no significant differences in rates of repair of drug-induced DNA damage between these cell lines.
It has been proposed that activation of tirapazamine by a nuclear reductase produces a high local concentration of tirapazamine radicals and multiple DNA strand breaks similar to those produced by high linear energy transfer (LET) radiation (Brown, 1993) . Consistent with this is the much lower sensitivity of the hypoxic cytotoxicity of tirapazamine to inhibition by oxygen than that reported for many other bioreductive drugs (Marshall and Rauth, 1988;  (Marshall and Rauth, 1986 ) and ascorbate has also been reported to reduce tirapazamine under both aerobic and hypoxic conditions (Silva and O'Brien, 1993 cell cultures (typically 105-106 cells ml-') as the rate of cellular metabolism will be greatly enhanced at the much higher cell densities in vivo (10'-109 cells ml-').
For any bioreductive drug that is selectively toxic towards hypoxic tumour cells both the level of tumour hypoxia and the activity of cellular reductases will be important 70 80 determinants of response to that drug. In order to predict the response of individual tumours to the drug the level of cic potency of hypoxia and relevant reductase activity could be measured sensitivity to ssb independently, using oxygen electrodes to assess hypoxia Le loss; (c), rate and immunoblot analysis or assaying I; U, RIF-1; V, for enzyme activity (Workman and Stratford, 1993; Patterson et al., 1995) . However, one of the problems in applying this enzyme-directed approach to predicting tumour response to tirapazamine is that it is not clear which bioreductive enzyme is responsible for activation of the drug. Although it is widely perceived that cytochrome p450 re possible that reductase is the critical enzyme, and a significant correlation r metabolism of has been reported between activity of this enzyme and xicity. Although tirapazamine cytotoxicity in a panel of human breast cancer )t been unequicell lines (Patterson et al., 1995) , no correlation was observed or the metabolic for a panel of human lung tumour lines (Barham et al., alently bound to 1995). Even if it was known which enzyme to assay for, it al., 1995). The would still be necessary to measure the level of hypoxia in oxicity correlates each tumour. We therefore propose that, for tirapazamine, similar ratio of the comet assay may be a more promising approach as DNA e in each of the damage measured using this assay should be a function of both oxygenation status and enzyme activity. In the present -tween hypoxic study hypoxic cytotoxicity of tirapazamine correlated with )f tirapazamine, DNA damage for six human and murine tumour cell lines.
and toxicity
We are currently exploring further the potential of using this that metabolism assay to predict the response of tumours to tirapazamine by s, measured as investigating the relationship between tirapazamine-induced Dxic cytotoxicity DNA damage and tirapazamine potentiation of tumour cell on et al., 1995).
killing by fractionated radiation. 
